Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fulvestrant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 10/20 | 0.76 |
| ▸ | ESRRA | P11474 | 9/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.76 |
| ▸ | PPARG | P37231 | 1/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.76 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ESRRB | O95718 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fulvestrant SCHEMBL8427428 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL14340043 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL22356606 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL23134939 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL20448785 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL23760281 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| SCHEMBL24511123 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| SCHEMBL23963146 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL22667548 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL7803375 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165225-A1 | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells | WISTAR INST (US) | 2024-05-23 | — | — | US | claimed |
| US-20190201526-A1 | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells | WISTAR INST (US) | 2019-07-04 | — | — | US | claimed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240165225-A1 | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells | WISTAR INST (US) | 2024-05-23 | — | — | US | disclosed |
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2022163670-A1 | CULTURE TECHNIQUE FOR DIFFERENTIATING OVARIAN TISSUE FROM PLURIPOTENT STEM CELLS | 国立大学法人九州大学 | 2022-08-04 | — | — | WO | disclosed |
| US-11229630-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | OLEMA PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3912680-A1 | TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE ANTI-ESTROGENIC DRUGS | Olema Pharmaceuticals, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3355884-B1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-8377991-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2274316-B1 | LIGANDS OF ESTROGEN RECEPTORS AND , METHOD OF THEIR PREPARATION AND PHARMACEUTICALS COMPRISING THEM | USTAV MOLEKULARNI GENETIKY AV CR V V I (CZ) | 2013-02-13 | — | — | EP | disclosed |
| US-8372887-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8334280-B2 | Ligands of estrogen receptors α and β, method of their preparation, and pharmaceuticals comprising them | Ustav Molekularni Genetikv AV CR, V.V.I. (CZ) | 2012-12-18 | — | — | US | disclosed |
| US-20120022167-A1 | Trans-Clomiphene for Metabolic Syndrome | REPROS THERAPEUTICS INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110118225-A1 | Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them | UNIVERZITA KARLOVA V PRAZE, PRIRODOVEDECKA FAKULTA UK (CZ) | 2011-05-19 | — | — | US | disclosed |
| US-7737185-B2 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090099265-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20070249726-A1 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672785-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885ESRRA 15/4885ESR2 6/4885 |
| US-20240165225-A1 | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells | ESRRG, ESR2, ESRRB | ESR1 6/4885ESRRA 4/4885ESR2 2/4885 |
| US-20190201526-A1 | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells | ESRRG, ESR2, ESRRB | ESR1 6/4885ESRRA 4/4885ESR2 2/4885 |
| US-20110118225-A1 | Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them | ESR2, GPER1, ESRRB | ESR1 4/4885ESRRA 6/4885ESR2 1/4885 |
| US-11229630-B2 | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885ESRRA 15/4885ESR2 6/4885 |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | ESR1 1/4885ESRRA 15/4885ESR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.